Concepedia

Author

Lorenzo Fornaro

Azienda Ospedaliera Universitaria PisanaORCID

Also Known As

Fornaro L, Fornaro, L., Fornaro, Lorenzo, L FORNARO, L Fornaro, L. Fornaro, L., Fornaro, LORENZO FORNARO, Lorenzo Fornaro, on behalf of the GICO group (Gruppo Italiano COlangiocarcinoma)

337

Publications

6.1K

Citations

34

H-Index

37

Concepts

All Affiliations

Azienda Ospedaliera Universitaria PisanaUniversity of PisaIstituti di Ricovero e Cura a Carattere ScientificoIstituto Oncologico VenetoFondazione IRCCS Istituto Nazionale dei Tumori
LF

About

Lorenzo Fornaro is an author at Azienda Ospedaliera Universitaria Pisana specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

20

29

2.7K

2

Gastroenterology

8

8

1.7K

3

Health Sciences

5

5

107

4

Hepatology

1

1

23

5

Immunology

1

1

51

Lorenzo Fornaro

×

76

Publications

4.8K

Citations

31

H-Index

YearCitations

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang,

The Lancet

2018

1.3K

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

Gianluca Masi, Fotios Loupakis, Lisa Salvatore,

The Lancet Oncology

2010

240

Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases

Gianluca Masi, Fotios Loupakis, Luca Emanuele Pollina,

Annals of Surgery

2009

234

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Miao‐Zhen Qiu, Do‐Youn Oh, Ken Kato,

BMJ

2024

195

Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy

Vincenzo Catalano, Fotios Loupakis, Francesco Graziano,

British Journal of Cancer

2009

191

Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis

Gianluca Masi, E. Vasile, Fotios Loupakis,

JNCI Journal of the National Cancer Institute

2010

188

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial

Gianluca Masi, Lisa Salvatore, Luca Boni,

Annals of Oncology

2015

164

Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

Charles S. Fuchs, Mustafa Özgüroğlu, Yung‐Jue Bang,

Gastric Cancer

2021

162

HER2 loss in HER2‐positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research

Filippo Pietrantonio, M. Caporale, Federica Morano,

International Journal of Cancer

2016

142

Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer

Vincenzo Catalano, Fotios Loupakis, Francesco Graziano,

Annals of Oncology

2011

114

Page 1